Ensuring data integrity in the pharmaceutical lifecycle: Challenges, principles, and global implications.

Data integrity is a cornerstone of the pharmaceutical sector's capacity to provide safe, efficacious, and high-quality medicinal products. It guarantees that data remains accurate, consistent, comprehensive, and dependable across the entire product lifecycle, encompassing research, clinical development, manufacturing, regulatory submissions, and post-marketing surveillance. This discourse explains the significance of data integrity in maintaining regulatory adherence, safeguarding patient welfare, and upholding quality benchmarks. It delves into the principles of ALCOA and ALCOA+, underscores the critical nature of Good Documentation Practices (GDP), and identifies prevalent threats such as data falsification, inadequate documentation, and insufficient system controls. Empirical case studies exemplify the grave repercussions of data breaches, alongside the advantages of robust data governance frameworks. The review further accentuates how compromised data can culminate in hazardous products and erosion of public confidence. Ultimately, it proposes methodologies for bolstering data integrity, fostering a culture of transparency, and ensuring regulatory conformity to facilitate consistent and reliable pharmaceutical operations globally.